한글목차

2023년 7개 주요 시장 전체에서 PsA 발병자는 4만 5,580명이었습니다. 이 중 미국이 18세 이상 남녀를 합해 총 2만 2,124명으로 가장 많은 환자 수를 차지했습니다. 일본은 2023년 PsA 발병자 중 가장 적은 341명을 차지했으며, 2023년 7개 주요 시장 전체에서 PsA 발병자는 154만 7,313명이었습니다. 이 중 미국이 18세 이상 남녀를 합해 76만 3,439명으로 가장 많은 환자 수를 차지했습니다. 일본은 2023년 PsA 유병자 중 가장 적은 1,2,063명을 차지했습니다. 주요 7개 시장 전체에서 PsA 유병자 수 증가의 주요 요인은 PsA 진단율의 전반적인 증가로 나타났습니다. 또한, GlobalData의 역학자들은 7개 주요 시장에서의 PsA 발병자 수와 유병자 수 증가는 각 시장의 인구통계학적 요인에 기인한다고 분석했습니다.

본 보고서는 주요 7개 시장(미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 일본)의 건선성 관절염(PsA)에 대해 조사 분석하여 위험인자 및 동반질환, 과거 역학 동향에 대한 정보를 제공합니다.

목차

제1장 건선성 관절염 : 주요 요약

• 촉매
• 관련 보고서
• 향후 보고서

제2장 역학

• 질환 배경
• 위험인자와 합병증
• 세계의 과거 동향
• 예측 방법
• PsA 역학 예측(2023-33년)
  • PsA 발증자수
  • PsA 발증자수 : 성별
  • PsA 발증자수 : 연령별
  • PsA 유병자수
  • PsA 유병자수 : 성별
  • PsA 유병자수 : 연령별
  • 유병자수 : 유형별
  • 유병자수 : 중증도별
  • 유병자수 : 합병증별
  • 건선을 수반하는 PsA 유병자수
• 논의
  • 역학 예측 인사이트
  • 분석의 한계
  • 분석의 강점

제3장 부록

영문목차

Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy that may be progressive and can lead to severe joint damage and disability (Ogdie and Gelfand, 2011). The disease is considered rare in the general population, but PsA affects up to 30% of people with psoriasis (Ogdie and Gelfand, 2011; National Psoriasis Foundation, 2024). It is estimated that more than 85% of PsA cases are preceded by psoriasis, which can vary in form and duration; the remaining PsA cases are diagnosed simultaneously with psoriasis or in the absence of skin disease (Gottlieb et al., 2008; Wilson et al., 2009). PsA is a highly heterogeneous disease that may present with nonspecific symptoms, often making diagnosis difficult (Ogdie and Gelfand, 2011). General symptoms associated with PsA include generalized fatigue, tenderness in tendons, swollen fingers and toes, stiffness and pain in joints, conjunctivitis, and nail changes (National Psoriasis Foundation, 2024). Historically, diagnosing PsA has been difficult due to the limited recognition of the disease and the highly heterogeneous diagnostic criteria. However, the recently developed Classification of Psoriatic Arthritis (CASPAR) criteria have become the most accepted standard for diagnosing PsA.

In 2023, there were 45,580 diagnosed incident cases of PsA across the 7MM. The US accounted for the majority of these cases, with 22,124 diagnosed incident cases of PsA in men and women combined, ages 18 years and older. Japan accounted for the fewest cases in 2023, with 341 diagnosed incident cases of PsA. In 2023, there were 1,547,313 diagnosed prevalent cases of PsA across the 7MM. The US accounted for the majority of these cases, with 763,439 diagnosed prevalent cases of PsA in men and women combined, ages 18 years and older. Japan accounted for the fewest cases in 2023, with 12,063 diagnosed prevalent cases of PsA. Due to the methodology used by GlobalData to obtain primary market research (PMR) data, the main driver of growth in the diagnosed prevalent cases of PsA across the 7MM is the overall increase in the diagnosis rate of PsA. Additionally, GlobalData epidemiologists attribute the increase in the diagnosed incident cases and diagnosed prevalent cases of PsA in the 7MM to population dynamics in each market.

Scope

• This report provides an overview of the risk factors, comorbidities, and global and historical trends for PsA across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for diagnosed incident cases of PsA and a 10-year forecast of diagnosed prevalent cases of PsA segmented by sex and age (beginning at age 18 years and ending at ages 85 years or older) in these markets.
• This report also includes an assessment of PsA severity, an analysis of diagnosed prevalent cases by subtype based on the Moll and Wright Criteria, data on prevalent PsA cases with comorbidities, and a forecast of prevalent PsA cases with psoriasis.
• The epidemiology model will provide additional clinically relevant segmentations, including a forecast for the total prevalent cases (diagnosed and undiagnosed) of PsA.

Reasons to Buy

The Psoriatic arthritis (PsA) epidemiology series will allow you to -

• Develop business strategies by understanding the trends shaping and driving the global PsA market.
• Quantify patient populations in the global PsA market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups that present the best opportunities for PsA therapeutics in each of the markets covered.

Table of Contents

Table of Contents

• About GlobalData

1 Psoriatic Arthritis: Executive Summary

• 1.1 Catalyst
• 1.2 Related reports
• 1.3 Upcoming reports

2 Epidemiology

• 2.1 Disease background
• 2.2 Risk factors and comorbidities
• 2.3 Global and historical trends
• 2.4 Forecast methodology
  • 2.4.1 Sources
  • 2.4.2 Forecast assumptions and methods
  • 2.4.3 Diagnosed incident cases of PsA
  • 2.4.4 Diagnosed prevalent cases of PsA
  • 2.4.5 Diagnosed prevalent cases of PsA by type
  • 2.4.6 Diagnosed prevalent cases of PsA by severity
  • 2.4.7 Diagnosed prevalent cases of PsA with comorbidity
  • 2.4.8 Diagnosed prevalent cases of PsA with psoriasis
• 2.5 Epidemiological forecast for PsA (2023-33)
  • 2.5.1 Diagnosed incident cases of PsA
  • 2.5.2 Sex-specific diagnosed incident cases of PsA
  • 2.5.3 Age-specific diagnosed incident cases of PsA
  • 2.5.4 Diagnosed prevalent cases of PsA
  • 2.5.5 Sex-specific diagnosed prevalent cases of PsA
  • 2.5.6 Age-specific diagnosed prevalent cases of PsA
  • 2.5.7 Diagnosed prevalent cases by type
  • 2.5.8 Diagnosed prevalent cases by severity
  • 2.5.9 Diagnosed prevalent cases by comorbidity
  • 2.5.10 Diagnosed prevalent cases of PsA with psoriasis
• 2.6 Discussion
  • 2.6.1 Epidemiological forecast insight
  • 2.6.2 Limitations of the analysis
  • 2.6.3 Strengths of the analysis

3 Appendix

• 3.1 Bibliography
• 3.2 Primary research - prescriber survey
• 3.3 Primary market research - Key opinion leaders (KOLs) interviewed for this report
  • 3.3.1 KOLs
• 3.4 About the authors
  • 3.4.1 Epidemiologist
  • 3.4.2 Reviewers
  • 3.4.3 Vice President of Disease Intelligence and Epidemiology
  • 3.4.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence
• Contact Us